

SESSION OF 2014

**SUPPLEMENTAL NOTE ON HOUSE RESOLUTION
NO. 6049**

As Amended by House Committee on Health
and Human Services

Brief*

HR 6049 would encourage the Kansas Department of Health and Environment (KDHE) to create a comprehensive Chronic Obstructive Pulmonary Disease (COPD) prevention and education state plan (the plan), in part to foster public awareness concerning the causes, diagnosis, and effective prevention of COPD. The resolution would require the plan to include strategies for reducing the burden of COPD and recommendations for:

- Prevention and early detection of COPD;
- Treatment and management of COPD to ensure access to state-of-the art care;
- Increase in public awareness, patient education, and proper medical management of COPD; and
- Improvement of COPD outcomes through increased funding and resources.

The resolution would make findings relating to COPD, including these:

- COPD is a chronic disease of the lung which cannot be cured;

*Supplemental notes are prepared by the Legislative Research Department and do not express legislative intent. The supplemental note and fiscal note for this bill may be accessed on the Internet at <http://www.kslegislature.org>

- COPD was the third leading cause of death in the year 2000 and is projected to be the third leading cause of death in the year 2012;
- COPD is the second leading cause of disability;
- Up to 70 percent of the costs of COPD are due to hospitalizations which can largely be prevented;
- COPD is a leading cause of death in Kansas with as many as 146.5 persons admitted to the hospital for every 100,000 persons in Kansas; and
- COPD is treatable and manageable.

Background

At the hearing before the House Committee on Health and Human Services, representatives of the Kansas Respiratory Care Society and GlaxoSmithKline testified in support of the resolution. According to proponent testimony, COPD awareness is low among the general public. The American Lung Association provided written testimony in support of the resolution.

KDHE provided written neutral testimony. There was no opponent testimony.

The House Committee amended the resolution at the request of GlaxoSmithKline to remove a requirement that KDHE create a state plan on COPD, and the dates in the resolution also were updated.